Cargando…

BET inhibitors as novel therapeutic agents in breast cancer

Tumoral cells not only depend on oncogenic abnormalities to maintain its malignant phenotype but on non-oncogenic vulnerabilities. Targeting epigenomics can modify specific cellular functions required for malignant transformation. The Bromodomain (BRD) family mediates their effect by recruiting prot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ocaña, Alberto, Nieto-Jiménez, Cristina, Pandiella, Atanasio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642636/ https://www.ncbi.nlm.nih.gov/pubmed/29050361 http://dx.doi.org/10.18632/oncotarget.19744

Ejemplares similares

Breast Cancer Heterogeneity and Response to Novel Therapeutics
por: Baliu-Piqué, Mariona, et al.
Publicado: (2020)

Neutrophils in cancer: prognostic role and therapeutic strategies
por: Ocana, Alberto, et al.
Publicado: (2017)

Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer
por: Noblejas-López, María del Mar, et al.
Publicado: (2019)

Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies
por: Ocana, Alberto, et al.
Publicado: (2017)

Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors
por: Nieto-Jiménez, Cristina, et al.
Publicado: (2017)

Enhanced Antitumoral Activity of Encapsulated BET Inhibitors When Combined with PARP Inhibitors for the Treatment of Triple-Negative Breast and Ovarian Cancers
por: Juan, Alberto, et al.
Publicado: (2022)

Antibody Conjugation of Nanoparticles as Therapeutics for Breast Cancer Treatment
por: Juan, Alberto, et al.
Publicado: (2020)

Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results
por: Ocaña, Alberto, et al.
Publicado: (2018)

Personalized therapies in the cancer "omics" era
por: Ocaña, Alberto, et al.
Publicado: (2010)

Proteolysis targeting chimeras (PROTACs) in cancer therapy
por: Ocaña, Alberto, et al.
Publicado: (2020)

DNA-damage related genes and clinical outcome in hormone receptor positive breast cancer
por: Nieto-Jiménez, Cristina, et al.
Publicado: (2016)

HER3 in cancer: from the bench to the bedside
por: Gandullo-Sánchez, Lucía, et al.
Publicado: (2022)

Mapping Bromodomains in breast cancer and association with clinical outcome
por: Pérez-Pena, Javier, et al.
Publicado: (2019)

An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy
por: Juan, Alberto, et al.
Publicado: (2020)

Considerations for the clinical development of immuno-oncology agents in cancer
por: Pandiella, Atanasio, et al.
Publicado: (2023)

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
por: Ocaña, Alberto, et al.
Publicado: (2020)

Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs
por: Díaz-Rodríguez, Elena, et al.
Publicado: (2021)

Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling
por: Montero, Juan Carlos, et al.
Publicado: (2015)

Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer
por: Nieto-Jimenez, Cristina, et al.
Publicado: (2020)

Generation of Antibody-Drug Conjugate Resistant Models
por: Gandullo-Sánchez, Lucía, et al.
Publicado: (2021)

Achilles' heel of triple negative cancer
por: Ocaña, Alberto, et al.
Publicado: (2014)

Achilles' heel of triple negative cancer
por: Ocaña, Alberto, et al.
Publicado: (2014)

Erratum: Achilles' heel of triple negative cancer
por: Ocaña, Alberto, et al.
Publicado: (2014)

MZ1 co-operates with trastuzumab in HER2 positive breast cancer
por: Noblejas-López, María del Mar, et al.
Publicado: (2021)

Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer
por: Montero, Juan Carlos, et al.
Publicado: (2022)

Expression of Erk5 in Early Stage Breast Cancer and Association with Disease Free Survival Identifies this Kinase as a Potential Therapeutic Target
por: Montero, Juan Carlos, et al.
Publicado: (2009)

Therapeutic potential of ERK5 targeting in triple negative breast cancer
por: Ortiz-Ruiz, María Jesús, et al.
Publicado: (2014)

Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2
por: Pandiella, Atanasio, et al.
Publicado: (2015)

Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers
por: Perez-Peña, Javier, et al.
Publicado: (2017)

Regulation of the prometastatic neuregulin–MMP13 axis by SRC family kinases: therapeutic implications
por: Orive‐Ramos, Ana, et al.
Publicado: (2017)

Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple‐negative breast cancer
por: Corrales‐Sánchez, Verónica, et al.
Publicado: (2020)

BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications
por: To, Kenneth K. W., et al.
Publicado: (2023)

Evaluation of transcriptionally regulated genes identifies NCOR1 in hormone receptor negative breast tumors and lung adenocarcinomas as a potential tumor suppressor gene
por: Noblejas-López, María del Mar, et al.
Publicado: (2018)

The emerging role of BET inhibitors in breast cancer
por: Andrikopoulou, A., et al.
Publicado: (2020)

Transcriptomic Profiles of CD47 in Breast Tumors Predict Outcome and Are Associated with Immune Activation
por: Noblejas-López, María del Mar, et al.
Publicado: (2021)

Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling
por: Cuenca-López, María D, et al.
Publicado: (2014)

In silico analyses identify gene-sets, associated with clinical outcome in ovarian cancer: role of mitotic kinases
por: Ocaña, Alberto, et al.
Publicado: (2016)

Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer
por: Noblejas-López, María del Mar, et al.
Publicado: (2022)

Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer
por: Serrano-Oviedo, Leticia, et al.
Publicado: (2020)

Achieving clinical success with BET inhibitors as anti-cancer agents
por: Shorstova, Tatiana, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4suhm4jap76g185ggugqtlnomt